Which second line treatments after ESA failure?

Oncotarget. 2017 Sep 14;8(45):78255-78256. doi: 10.18632/oncotarget.20873. eCollection 2017 Oct 3.

Authors

Sophie Park¹, Charikleia Kelaidi¹, François Dreyfus¹

Affiliation

¹ Sophie Park: CHU Grenoble Alpes, Clinique Universitaire d'Hématologie, GRENOBLE Cedex, FRANCE.

No abstract available

Keywords: azacitidine; erythropoiesis stimulating agents; lenalidomide; myelodysplastic syndromes; outcome.

Publication types

Editorial